Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21801153 | 0.84 | ABCB1 (0.53) | MAOBCYSLTR1ABCB1CYP1A1CYP1A2 | |
| SCHEMBL21801308 | 0.83 | ABCB1 (0.52) | MAOBCYSLTR1ABCB1CYP1A1CYP1A2 | |
| SCHEMBL30744078 | 0.82 | CYSLTR1 (0.50) | CYSLTR1 | |
| SCHEMBL21801075 | 0.82 | CYSLTR1 (0.50) | CYSLTR1 | |
| SCHEMBL21801192 | 0.82 | TNKS (0.45) | MAOBMAOACYSLTR1ABCB1CYP1A1 | |
| SCHEMBL21801146 | 0.81 | CYSLTR1 (0.43) | MAOBMAOACYSLTR1ABCB1CYP1A1 | |
| SCHEMBL21801178 | 0.81 | CYP1A1 (0.67) | MAOBABCB1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL21865610 | 0.81 | CYSLTR1 (0.53) | MAOBMAOACYSLTR1ABCB1CYP1A1 | |
| SCHEMBL21801271 | 0.81 | ABCB1 (0.52) | MAOBCYSLTR1ABCB1CYP1A1CYP1A2 | |
| SCHEMBL30744107 | 0.81 | ABCB1 (0.52) | MAOBCYSLTR1ABCB1CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020052774-A1 | FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | disclosed |